Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 10/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1535859 | 0.93 | ALDH1A1 (0.37) | THRBTHRASLC29A1HRH3MAPK1 | |
| SCHEMBL674518 | 0.93 | THRB (0.37) | THRBTHRASLC29A1HRH3 | |
| SCHEMBL28889977 | 0.90 | THRB (0.36) | THRBTHRASLC29A1HRH3MAPK1 | |
| SCHEMBL18887954 | 0.89 | THRB (0.38) | THRBTHRAHRH3 | |
| SCHEMBL673451 | 0.88 | THRB (0.35) | THRBTHRASLC29A1HRH3 | |
| Aziridine SCHEMBL11905307 | 0.88 | THRB (0.34) | THRBTHRAHRH3 | |
| SCHEMBL17118258 | 0.88 | ALDH1A1 (0.33) | THRBTHRAMAPK1HIF1A | |
| SCHEMBL25420260 | 0.86 | THRB (0.34) | THRBTHRAHRH3 | |
| SCHEMBL20017398 | 0.86 | TP53 (0.37) | THRBTHRAHRH3MAPK1HIF1A | |
| SCHEMBL15962171 | 0.85 | THRB (0.33) | THRBTHRASLC29A1MAPK1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11292771-B2 | Amidine catalyst for curable compositions | SIKA TECHNOLOGY AG (CH) | 2022-04-05 | — | — | US | disclosed |
| EP-3757094-A1 | AMIDINE CATALYST FOR CURABLE COMPOSITIONS | SIKA TECHNOLOGY AG (CH) | 2020-12-30 | — | — | EP | disclosed |
| EP-3283550-B1 | CATALYST CONTAINING AMIDINE GROUPS | SIKA TECH AG (CH) | 2020-12-16 | — | — | EP | disclosed |
| EP-3294803-B1 | GUANIDINE GROUP CONTAINING CATALYST | SIKA TECH AG (CH) | 2020-12-09 | — | — | EP | disclosed |
| EP-3310763-B1 | AMIDINE CATALYST FOR CURABLE COMPOSITIONS | SIKA TECH AG (CH) | 2020-11-18 | — | — | EP | disclosed |
| US-20200231548-A1 | AMIDINE CATALYST FOR CURABLE COMPOSITIONS | SIKA TECHNOLOGY AG (CH) | 2020-07-23 | — | — | US | disclosed |
| US-10647681-B2 | Amidine catalyst for curable compositions | SIKA TECHNOLOGY AG (CH) | 2020-05-12 | — | — | US | disclosed |
| US-10414875-B2 | Catalyst containing guanidine groups | SIKA TECHNOLOGY AG (CH) | 2019-09-17 | — | — | US | disclosed |
| US-10392480-B2 | Catalyst containing amidine groups | SIKA TECHNOLOGY AG (CH) | 2019-08-27 | — | — | US | disclosed |
| US-20180179165-A1 | AMIDINE CATALYST FOR CURABLE COMPOSITIONS | SIKA TECHNOLOGY AG (CH) | 2018-06-28 | — | — | US | disclosed |
| US-20180171082-A1 | CATALYST CONTAINING AMIDINE GROUPS | SIKA TECHNOLOGY AG (CH) | 2018-06-21 | — | — | US | disclosed |
| US-20180148545-A1 | CATALYST CONTAINING GUANIDINE GROUPS | SIKA TECHNOLOGY AG (CH) | 2018-05-31 | — | — | US | disclosed |
| EP-3310763-A1 | AMIDINE CATALYST FOR CURABLE COMPOSITIONS | Sika Technology AG (CH) | 2018-04-25 | — | — | EP | disclosed |
| EP-3283550-A1 | AMIDINE-GROUP CONTAINING CATALYST | Sika Technology AG (CH) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016207156-A1 | AMIDINE CATALYST FOR CURABLE COMPOSITIONS | SIKA TECHNOLOGY AG (CH) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016166336-A1 | AMIDINE-GROUP CONTAINING CATALYST | SIKA TECHNOLOGY AG (CH) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414875-B2 | Catalyst containing guanidine groups | GMPS, GMNN, RNMT | THRB 4829/4885THRA 4777/4885SLC29A1 261/4885 |
| US-20180148545-A1 | CATALYST CONTAINING GUANIDINE GROUPS | GMPS, RNMT, GMNN | THRB 4851/4885THRA 4804/4885SLC29A1 203/4885 |
| US-11292771-B2 | Amidine catalyst for curable compositions | ADM2, GMNN, ARG1 | THRB 4821/4885THRA 4748/4885SLC29A1 899/4885 |
| US-20200231548-A1 | AMIDINE CATALYST FOR CURABLE COMPOSITIONS | ADM2, GMNN, ARG1 | THRB 4821/4885THRA 4748/4885SLC29A1 899/4885 |
| US-20180179165-A1 | AMIDINE CATALYST FOR CURABLE COMPOSITIONS | ADM2, GMNN, ARG1 | THRB 4821/4885THRA 4748/4885SLC29A1 899/4885 |
| US-10647681-B2 | Amidine catalyst for curable compositions | ADM2, GMNN, ARG1 | THRB 4821/4885THRA 4748/4885SLC29A1 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.